US Patent No: 8,039,009
Number of patents in Portfolio can not be more than 2000
Modified release formulations of memantine oral dosage forms
Stats
-
Oct 18, 2011
Issued date -
Jun 16, 2005
filing date -
11/155,330
serial no -
In Force
status
Importance
Loading Importance Indicators...
Abstract
The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
Loading the Abstract Image...
First Claim
Related Publications
Loading Related Publications...
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art
| Patent Info | (Count) | # Cites | Year |
|---|---|---|---|
|
|
|||
| 5,061,703 Adamantane derivatives in the prevention and treatment of cerebral ischemia | 34 | 1990 | |
| 5,382,601 Memantine-containing solid pharmaceutical dosage forms having an extended two-stage release profile and production thereof | 24 | 1993 | |
| 6,034,134 1-Amino-alkylcyclohexane NMDA receptor antagonists | 20 | 1998 | |
| 6,071,966 1-amino-alkylcyclohexane NMDA receptor antagonists | 8 | 1998 | |
|
|
|||
| 5,334,618 Method of preventing NMDA receptor-mediated neuronal damage | 15 | 1992 | |
| 5,506,231 Treatment of aids dementia, myelopathy and blindness | 8 | 1993 | |
| 5,614,560 Method of preventing NMDA receptor-mediated neuronal damage | 24 | 1995 | |
|
|
|||
| 2006/0002,999 Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane | 6 | 2005 | |
| 2007/0065,512 MODIFIED AND IMMEDIATE RELEASE FORMULATIONS OF MEMANTINE | 11 | 2006 | |
| 2009/0247,644 MEMANTINE FORMULATIONS | 1 | 2009 | |
|
|
|||
| 5,582,837 Alkyl-substituted cellulose-based sustained-release oral drug dosage forms | 82 | 1995 | |
| 5,972,389 Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter | 116 | 1996 | |
|
|
|||
| 2006/0142,398 Method and composition for adminstering an NMDA receptor antagonist to a subject | 12 | 2005 | |
|
|
|||
| 6,479,553 Use of certain affinity NMDA antagonists as antidepressants | 12 | 2000 | |
|
|
|||
| 5,007,790 Sustained-release oral drug dosage form | 130 | 1989 | |
|
|
|||
| 6,413,556 Aqueous anti-apoptotic compositions | 5 | 2000 | |
|
|
|||
| 6,194,000 Analgesic immediate and controlled release pharmaceutical composition | 56 | 1998 | |
|
|
|||
| 4,273,774 Central nervous system compositions and method | 17 | 1979 | |
|
|
|||
| 2005/0245,617 Methods and compositions for the treatment of CNS-related conditions | 13 | 2005 | |
|
|
|||
| 6,444,702 Aminoadamantane derivatives as therapeutic agents | 14 | 2000 | |
|
|
|||
| 2004/0102,525 Compositions and methods of treating neurological disease and providing neuroprotection | 22 | 2003 | |
Patent Citation Ranking
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 3.5 Year Payment | $1600.00 | $800.00 | $400.00 | Apr 18, 2015 |
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Apr 18, 2019 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Apr 18, 2023 |
| Fee | Large entity fee | small entity fee | micro entity fee |
|---|---|---|---|
| Surcharge - 3.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
| Surcharge - 7.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
| Surcharge - 11.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
| Surcharge after expiration - Late payment is unavoidable | $700.00 | $350.00 | $175.00 |
| Surcharge after expiration - Late payment is unintentional | $1,640.00 | $820.00 | $410.00 |